These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 11195542)

  • 1. [Fluvoxamine (fevarin) in the treatment of depression].
    Sheĭfer MS; Tsybina MI; Davydenko MV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2000; 100(12):64-7. PubMed ID: 11195542
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Fluvoxamine (fevarin) in psychogenic depression].
    Dubnitskaia EB
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(12):48-50. PubMed ID: 11811127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic action and efficiency of fevarin (fluvoxamine) in patients with non-psychotic anxious and apathic-adynamic depressions].
    Neznamov GG; Siuniakov SA; Teleshova ES; Dorofeeva OA; Chumakov DB; Davydova IA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2001; 101(8):19-24. PubMed ID: 11552628
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Characteristics of clinical effects of paxil in the treatment of endogenous depression].
    Panteleeva GP; Korenev AN; Khananashvili MM; Oleĭchik IV; Kaleda VG
    Zh Nevrol Psikhiatr Im S S Korsakova; 1998; 98(6):26-31. PubMed ID: 9677694
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Concentration-response relationship for fluvoxamine using remission as an endpoint: a receiver operating characteristics curve analysis in major depression.
    Suzuki Y; Fukui N; Sawamura K; Sugai T; Watanabe J; Ono S; Inoue Y; Ozdemir V; Someya T
    J Clin Psychopharmacol; 2008 Jun; 28(3):325-8. PubMed ID: 18480690
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Maprotiline versus fluvoxamine: comparison of their effects on the hypothalamo-hypophyseal-thyroid axis].
    De Mendonça Lima CA; Vandel S; Bonin B; Bechtel P; Carron R
    Encephale; 1997; 23(1):48-55. PubMed ID: 9172968
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effects of a 5-hydroxytryptamine 1A receptor gene polymorphism on the clinical response to fluvoxamine in depressed patients.
    Suzuki Y; Sawamura K; Someya T
    Pharmacogenomics J; 2004; 4(4):283-6. PubMed ID: 15148501
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The influence of lithium on fluvoxamine therapeutic efficacy and pharmacokinetics in depressed patients on combined fluvoxamine-lithium therapy.
    Miljković BR; Pokrajac M; Timotijević I; Varagić V
    Int Clin Psychopharmacol; 1997 Jul; 12(4):207-12. PubMed ID: 9347381
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suitable dose and duration of fluvoxamine administration to treat depression.
    Morishita S; Arita S
    Psychiatry Clin Neurosci; 2003 Apr; 57(2):177-81. PubMed ID: 12667164
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fluvoxamine for premenstrual dysphoric disorder: a pilot study.
    Freeman EW; Rickels K; Sondheimer SJ
    J Clin Psychiatry; 1996; 57 Suppl 8():56-9; discussion 60. PubMed ID: 8698682
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The status of fluvoxamine among the antidepressive agents].
    Svestka J; Cesková E; Rysánek R; Obrovská V; Kamenická V
    Cesk Psychiatr; 1992 Sep; 88(5):209-19. PubMed ID: 1451197
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effect of mexidol in the combination with antidepressants on sleep disturbance in young patients with panic disorder].
    Kursakov ES; Remizevich RS
    Zh Nevrol Psikhiatr Im S S Korsakova; 2013; 113(2):33-8. PubMed ID: 23528580
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparative study of the efficacy and safety profiles between fluvoxamine and nortriptyline in Japanese patients with major depression.
    Otsubo T; Akimoto Y; Yamada H; Koda R; Aoyama H; Tanaka K; Mimura M; Nakagome K; Kamijima K
    Pharmacopsychiatry; 2005 Jan; 38(1):30-5. PubMed ID: 15706464
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder.
    Davidson J; Yaryura-Tobias J; DuPont R; Stallings L; Barbato LM; van der Hoop RG; Li D
    J Clin Psychopharmacol; 2004 Apr; 24(2):118-25. PubMed ID: 15206657
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An open trial of fluvoxamine therapy for panic disorder complicated by depression.
    Spiegel DA; Saeed SA; Bruce TJ
    J Clin Psychiatry; 1996; 57 Suppl 8():37-40; discussion 40-1. PubMed ID: 8698679
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Methylphenidate augmentation of fluvoxamine for treatment-resistant depression: a case report and review literature].
    Buhagiar K; Cassar J
    Turk Psikiyatri Derg; 2007; 18(2):179-83. PubMed ID: 17566884
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Orphan nuclear receptor Rev-erb alpha gene (NR1D1) and fluvoxamine response in major depressive disorder in the Japanese population.
    Kishi T; Kitajima T; Ikeda M; Yamanouchi Y; Kinoshita Y; Kawashima K; Okochi T; Ozaki N; Iwata N
    Neuropsychobiology; 2009; 59(4):234-8. PubMed ID: 19571598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An open-label pilot study of fluvoxamine for mixed anxiety-depression.
    Houck C
    Psychopharmacol Bull; 1998; 34(2):225-7. PubMed ID: 9641005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Potential benefits of slow titration of paroxetine treatment in an elderly population: eight-week results from a naturalistic setting.
    Gibiino S; Mori E; De Ronchi D; Serretti A
    J Clin Psychopharmacol; 2013 Aug; 33(4):565-9. PubMed ID: 23764690
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics and efficacy of fluvoxamine and amitriptyline in depression.
    Vezmar S; Miljkovic B; Vucicevic K; Timotijevic I; Prostran M; Todorovic Z; Pokrajac M
    J Pharmacol Sci; 2009 May; 110(1):98-104. PubMed ID: 19444001
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.